TipRanks
Go Ultimate55% OFF
PC:ADCEN

Adcendo: Valuation, Funding & Investors

Adcendo is a biotechnology company specializing in the development of first-in-class antibody-drug conjugates (ADCs) aimed at treating cancers with high unmet medical needs. The company is advancing multiple ADC programs into clinical trials to establish clinical proof of concept, focusing on innovative treatments that target specific cancer pathways.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$135M
Total Funding Rounds
1
Latest Funding Amount
$135M
Latest Funding Round
Series B

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Aug 14, 2025Series B$135.00M―

Investors

Investor NameFunding Round
TCGXSeries B
Logos CapitalSeries B
TPGSeries B
Orbimed AdvisorsSeries B
Venrock Healthcare Capital PartnersSeries B
Surveyor CapitalSeries B

Similar Companies

A snapshot of private companies similar to Adcendo, helping you discover and navigate related company profiles.

Related News and Analysis